Progress of targeted therapy for primary central nervous system lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 182-185, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-929755
ABSTRACT
Primary central nervous system lymphoma (PCNSL) is a rare invasive non-Hodgkin lymphoma. Although high dose methotrexate-based induced chemotherapy regimen has significantly improved prognosis of patients, 30 percent -40 percent of patients still relapse with poor prognosis. With the development of molecular biology, new targeted drugs like cell signaling pathway kinase inhibitors have become new treatment options for PCNSL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS